Delivery

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

ZURICH, Jan. 12, 2026 /PRNewswire/ — NewcelX Ltd. (Nasdaq: NCEL) (“NewcelX” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research…

Read more

Savvy Updates 2/17/25: 1st Rapid-Acting Biosimilar Insulin Approved, UVa AI-Powered Insulin Delivery, Susvimo for Diabetic Macular Edema, Oral Insulin Prevention Trial, GLP-1 Agonists Adhesive Capsulitis D, Protein-Rich, Low-Carb Diet & RA, D & Gum Disease & Flossing, Bone-Derived Hormone DKD, Insulin Resistance Predict OA, aD & Antibiotic-Resistance to Staph, ScotteVest & LOTS of POCKETS

In this week’s issue of The Savvy Diabetic:  1st Rapid-Acting Biosimilar Insulin Approved UVa AI-Powered Insulin Delivery Susvimo for Diabetic Macular Edema Oral Insulin Prevention Trial (PDF) GLP-1 Agonists Increased…

Read more